Targeting the epithelial cells in fibrosis: A new concept for an old disease

Drug Discovery Today

Volumn 18, Issue 11-12, 2013, Pages 582-591

  Moll, Solange ^a   Chaykovska, Lyubov ^b   Meier, Matthias ^c   Budd, David C ^d,e   Formentini, Ivan ^c   Pomposiello, Silvia ^c   Prunotto, Marco ^c  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d HOFFMANN LA ROCHE INC   (United States)

^e GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; ACETYLCYSTEINE; AKB 9875; AM 152; ANTIFIBROTIC AGENT; ATRASENTAN; BARDOXOLONE; BORTEZOMIB; BOSENTAN; CARLUMAB; ETANERCEPT; EVEROLIMUS; EXC 001; FG 3019; FG 4592; FRESOLIMUMAB; GKT 137831; GLYCEROL; GRN 510; GS 6624; IMATINIB; LY 2382770; MACITENTAN; MMI 0100; MONOCLONAL ANTIBODY; NAFB 002; NINTEDANIB; PIRFENIDONE; PLATELET DERIVED GROWTH FACTOR; PRM 151; PXS 4728; QAX 576; RAPAMYCIN; REFANALIN; RUXOLITINIB; SAR 100842; SDP 051; TANZISERTIB; TAT 153; THALIDOMIDE; THR 123; TRALOKINUMAB; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE KIDNEY FAILURE; ANTIOXIDANT ACTIVITY; CELL DIFFERENTIATION; CELL REGENERATION; CHRONIC KIDNEY DISEASE; CONNECTIVE TISSUE; DISEASE SEVERITY; DNA DAMAGE; DRUG TARGETING; EFFECTOR CELL; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; EXTRACELLULAR MATRIX; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; HYPOTHESIS; IN VITRO STUDY; IN VIVO STUDY; KIDNEY; KIDNEY FAILURE; KIDNEY FIBROSIS; LIVER CELL; LIVER FIBROSIS; LUNG FIBROSIS; MOLECULARLY TARGETED THERAPY; MYOFIBROBLAST; NONHUMAN; OXIDATIVE STRESS; PROTEIN PROCESSING; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; STELLATE CELL; TISSUE REPAIR; WOUND HEALING;

ANIMALS; EPITHELIAL CELLS; FIBROSIS; HUMANS; MYOFIBROBLASTS;

EID: 84878885988     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.01.006     Document Type: Review

References (92)

1. A. Bohle Pathogenesis of chronic renal failure in the primary glomerulopathies, renal vasculopathies, and chronic interstitial nephritides Kidney Int. Suppl. 54 1996 S2 S9
2. A.A. Eddy, and E.G. Neilson Chronic kidney disease progression J. Am. Soc. Nephrol. 17 2006 2964 2966
3. L.G. Fine Mechanisms of tubulo-interstitial injury in progressive renal diseases Eur. J. Clin. Invest. 23 1993 259 265
4. M. Zeisberg, and E.G. Neilson Mechanisms of tubulointerstitial fibrosis J. Am. Soc. Nephrol. 21 2010 1819 1834
5. J.M. Turner Treatment of chronic kidney disease Kidney Int. 81 2012 351 362
6. P. Cravedi Proteinuria should be used as a surrogate in CKD Nat. Rev. Nephrol. 8 2012 301 306
7. M.A. Onuigbo Can ACE inhibitors and angiotensin receptor blockers be detrimental in CKD patients? Nephron Clin. Pract. 118 2011 c407 c419
8. P. Ruggenenti Role of remission clinics in the longitudinal treatment of CKD J. Am. Soc. Nephrol. 19 2008 1213 1224
9. E.T. Rosolowsky Risk for ESRD in type 1 diabetes remains high despite renoprotection J. Am. Soc. Nephrol. 22 2011 545 553
10. G. Raghu Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials Am. J. Respir. Crit. Care Med. 185 2012 1044 1048
11. G. Gabbiani Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction Experientia 27 1971 549 550
12. B. Hinz Recent developments in myofibroblast biology: paradigms for connective tissue remodeling Am. J. Pathol. 180 2012 1340 1355
13. B. Hinz The myofibroblast: one function, multiple origins Am. J. Pathol. 170 2007 1807 1816
14. B. Hinz The myofibroblast: paradigm for a mechanically active cell J. Biomech. 43 2010 146 155
15. J. Varga, and D. Abraham Systemic sclerosis: a prototypic multisystem fibrotic disorder J. Clin. Invest. 117 2007 557 567
16. F.P. Russo The bone marrow functionally contributes to liver fibrosis Gastroenterology 130 2006 1807 1821
17. B.D. Humphreys Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis Am. J. Pathol. 176 2010 85 97
18. S.L. Friedman Evolving challenges in hepatic fibrosis Nat. Rev. Gastroenterol. Hepatol. 7 2010 425 436
19. R. Kalluri EMT: when epithelial cells decide to become mesenchymal-like cells J. Clin. Invest. 119 2009 1417 1419
20. A.B. Farris Morphometric and visual evaluation of fibrosis in renal biopsies J. Am. Soc. Nephrol. 22 2011 176 186
21. R.L. Amdur Outcomes following diagnosis of acute renal failure in U.S. veterans: focus on acute tubular necrosis Kidney Int. 76 2009 1089 1097
22. A. Ishani Acute kidney injury increases risk of ESRD among elderly J. Am. Soc. Nephrol. 20 2009 223 228
23. L.J. Lo Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease Kidney Int. 76 2009 893 899
24. R. Wald Chronic dialysis and death among survivors of acute kidney injury requiring dialysis J. Am. Med. Assoc. 302 2009 1179 1185
25. L.S. Chawla The severity of acute kidney injury predicts progression to chronic kidney disease Kidney Int. 79 2011 1361 1369
26. L.G. Fine Cell-cell cross-talk in the pathogenesis of renal interstitial fibrosis Kidney Int. Suppl. 49 1995 S48 S50
27. C.E. Alpers Human renal cortical interstitial cells with some features of smooth muscle cells participate in tubulointerstitial and crescentic glomerular injury J. Am. Soc. Nephrol. 5 1994 201 209
28. L. Yang Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury Nat. Med. 16 2010 535 543 531p following 143
29. R. Koesters Tubular overexpression of transforming growth factor-beta1 induces autophagy and fibrosis but not mesenchymal transition of renal epithelial cells Am. J. Pathol. 177 2010 632 643
30. B. Bielesz Epithelial Notch signaling regulates interstitial fibrosis development in the kidneys of mice and humans J. Clin. Invest. 120 2010 4040 4054
31. L. Yang Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury Nat. Med. 16 2010 535 543 531p following 143
32. I. Grgic Targeted proximal tubule injury triggers interstitial fibrosis and glomerulosclerosis Kidney Int. 82 2012 172 183
33. K.A. Nath Renal response to repetitive exposure to heme proteins: chronic injury induced by an acute insult Kidney Int. 57 2000 2423 2433
34. M.A. Venkatachalam Acute kidney injury: a springboard for progression in chronic kidney disease Am. J. Physiol. Renal Physiol. 298 2010 F1078 F1094
35. D.W. Visscher, and J.L. Myers Histologic spectrum of idiopathic interstitial pneumonias Proc. Am. Thorac. Soc. 3 2006 322 329
36. S. Harari, and A. Caminati IPF: new insight on pathogenesis and treatment Allergy 65 2010 537 553
37. Z.H. Hoo, and M.K. Whyte Idiopathic pulmonary fibrosis Thorax 2011
38. A.L. Degryse Repetitive intratracheal bleomycin models several features of idiopathic pulmonary fibrosis Am. J. Physiol. Lung Cell Mol. Physiol. 299 2010 L442 L452
39. N. Khalil Increased production and immunohistochemical localization of transforming growth factor-beta in idiopathic pulmonary fibrosis Am. J. Respir. Cell Mol. Biol. 5 1991 155 162
40. H.N. Antoniades Platelet-derived growth factor in idiopathic pulmonary fibrosis J. Clin. Invest. 86 1990 1055 1064
41. J.R. Nash Expression of tumour necrosis factor-alpha in cryptogenic fibrosing alveolitis Histopathology 22 1993 343 347
42. M. Selman, and A. Pardo The epithelial/fibroblastic pathway in the pathogenesis of idiopathic pulmonary fibrosis Am. J. Respir. Cell Mol. Biol. 29 Suppl 2003 S93 S97
43. L.S. Chawla, and P.L. Kimmel Acute kidney injury and chronic kidney disease: an integrated clinical syndrome Kidney Int. 82 2012 516 524
44. L. Richeldi, and R.M. du Bois Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program Expert Rev. Respir. Med. 5 2011 473 481
45. M.E. Cho, and J.B. Kopp Pirfenidone: an anti-fibrotic therapy for progressive kidney disease Expert Opin. Investig. Drugs 19 2010 275 283
46. C.J. Schaefer Antifibrotic activities of pirfenidone in animal models Eur. Respir. Rev. 20 2011 85 97
47. H. Trachtman A phase 1, single-dose study of fresolimumab, an anti-TGF-beta antibody, in treatment-resistant primary focal segmental glomerulosclerosis Kidney Int. 79 2011 1236 1243
48. Q. Wang Cooperative interaction of CTGF and TGF-beta in animal models of fibrotic disease Fibrogen. Tissue Repair 4 2011 4
49. S.G. Adler Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria Clin. J. Am. Soc. Nephrol. 5 2010 1420 1428
50. S. Mizuno HGF as a renotrophic and anti-fibrotic regulator in chronic renal disease Front. Biosci. 13 2008 7072 7086
51. W.H. Kim Growth inhibition and apoptosis in liver myofibroblasts promoted by hepatocyte growth factor leads to resolution from liver cirrhosis Am. J. Pathol. 166 2005 1017 1028
52. J. Yang, and Y. Liu Delayed administration of hepatocyte growth factor reduces renal fibrosis in obstructive nephropathy Am. J. Physiol. Renal Physiol. 284 2003 F349 F357
53. Y. Liu Endogenous hepatocyte growth factor ameliorates chronic renal injury by activating matrix degradation pathways Kidney Int. 58 2000 2028 2043
54. S. Mizuno, and T. Nakamura Suppressions of chronic glomerular injuries and TGF-beta 1 production by HGF in attenuation of murine diabetic nephropathy Am.J. Physiol. Renal Physiol. 286 2004 F134 F143
55. J.M. Cruzado Regression of advanced diabetic nephropathy by hepatocyte growth factor gene therapy in rats Diabetes 53 2004 1119 1127
56. K. Puthawala Inhibition of integrin alpha(v)beta6, an activator of latent transforming growth factor-beta, prevents radiation-induced lung fibrosis Am. J. Respir. Crit. Care Med. 177 2008 82 90
57. K. Hahm Alphav beta6 integrin regulates renal fibrosis and inflammation in Alport mouse Am. J. Pathol. 170 2007 110 125
58. J.P. Pradere Lysophosphatidic acid and renal fibrosis Biochim. Biophys. Acta 1781 2008 582 587
59. J.W. Choi LPA receptors: subtypes and biological actions Annu. Rev. Pharmacol. Toxicol. 50 2010 157 186
60. J. Heusinger-Ribeiro Expression of connective tissue growth factor in human renal fibroblasts: regulatory roles of RhoA and cAMP J. Am. Soc. Nephrol. 12 2001 1853 1861
61. T.A. Wynn, and T.R. Ramalingam Mechanisms of fibrosis: therapeutic translation for fibrotic disease Nat. Med. 18 2012 1028 1040
62. P. Fioretto Reversal of lesions of diabetic nephropathy after pancreas transplantation N. Engl. J. Med. 339 1998 69 75
63. P. Fioretto Remodeling of renal interstitial and tubular lesions in pancreas transplant recipients Kidney Int. 69 2006 907 912
64. Y. Jin A systems approach identifies HIPK2 as a key regulator of kidney fibrosis Nat. Med. 18 2012 580 588
65. M.A. Calzado HIPK2: a versatile switchboard regulating the transcription machinery and cell death Cell Cycle 6 2007 139 143
66. G. D'Orazi Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis Nat. Cell Biol. 4 2002 11 19
67. W. Lee Homeodomain-interacting protein kinases (Hipks) promote Wnt/Wg signaling through stabilization of beta-catenin/Arm and stimulation of target gene expression Development 136 2009 241 251
68. W. Lee Hipk is an essential protein that promotes Notch signal transduction in the Drosophila eye by inhibition of the global co-repressor Groucho Dev. Biol. 325 2009 263 272
69. T.G. Hofmann HIPK2 regulates transforming growth factor-beta-induced c-Jun NH(2)-terminal kinase activation and apoptosis in human hepatoma cells Cancer Res. 63 2003 8271 8277
70. W.H. Moolenaar The ins and outs of lysophosphatidic acid signaling Bioessays 26 2004 870 881
71. J. Chun International Union of Basic and Clinical Pharmacology, LXXVIII. Lysophospholipid receptor nomenclature Pharmacol. Rev. 62 2010 579 587
72. E.J. Goetzl Gelsolin binding and cellular presentation of lysophosphatidic acid J. Biol. Chem. 275 2000 14573 14578
73. C. Stortelers Multiple actions of lysophosphatidic acid on fibroblasts revealed by transcriptional profiling BMC Genomics 9 2008 387
74. S.N. Georas Lysophosphatidic acid is detectable in human bronchoalveolar lavage fluids at baseline and increased after segmental allergen challenge Clin. Exp. Allergy 37 2007 311 322
75. A.M. Tager The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak Nat. Med. 14 2008 45 54
76. M. Funke The lysophosphatidic acid receptor LPA1 promotes epithelial cell apoptosis after lung injury Am. J. Respir. Cell Mol. Biol. 46 2012 355 364
77. M.Y. Xu Lysophosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q) Am. J. Pathol. 174 2009 1264 1279
78. R.G. Jenkins Ligation of protease-activated receptor 1 enhances alpha(v)beta6 integrin-dependent TGF-beta activation and promotes acute lung injury J. Clin. Invest. 116 2006 1606 1614
79. H. Geng Lysophosphatidic acid increases proximal tubule cell secretion of profibrotic cytokines PDGF-B and CTGF through LPA2- and Galphaq-mediated Rho and alphavbeta6 integrin-dependent activation of TGF-beta Am. J. Pathol. 181 2012 1236 1249
80. K. Wallace Liver fibrosis Biochem. J. 411 2008 1 18
81. R. Malik The role of non-parenchymal cells in liver growth Semin. Cell Dev. Biol. 13 2002 425 431
82. M.R. Ebrahimkhani Stimulating healthy tissue regeneration by targeting the 5-HT(2)B receptor in chronic liver disease Nat. Med. 17 2011 1668 1673
83. C.P. Denton Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192 Arthritis Rheum. 56 2007 323 333
84. A. Kekewska Antiserotonergic properties of terguride in blood vessels, platelets, and valvular interstitial cells J. Pharmacol. Exp. Ther. 340 2012 369 376
85. S.A. Antoniu Terguride for pulmonary arterial hypertension Expert Opin. Ther. Targets 15 2011 1333 1335
86. V. Barry-Hamilton Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment Nat. Med. 16 2010 1009 1017
87. X. Du Involvement of matrix metalloproteinase-2 in the development of renal interstitial fibrosis in mouse obstructive nephropathy Lab. Invest. 92 2012 1149 1160
88. T.A. Wynn Fibrosis under arrest Nat. Med. 16 2010 523 525
89. T.A. Wynn Cellular and molecular mechanisms of fibrosis J. Pathol. 214 2008 199 210
90. G.M. Walsh Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD Curr. Opin. Investig. Drugs 11 2010 1305 1312
91. M.C. Thomas, and M.E. Cooper Diabetes: bardoxolone improves kidney function in type 2 diabetes Nat. Rev. Nephrol. 7 2011 552 553
92. M. Herz Effects of high dose aleglitazar on renal function in patients with type 2 diabetes Int. J. Cardiol. 151 2011 136 142